Skip main navigation
International Stroke Conference 2022 Moderated Poster Abstracts
Session Title: Acute Nonendovascular Treatment Moderated Poster Tour

Abstract WMP9: Pharmacological Characterization Of The Water Soluble Neurosteroid NTS-104 In The Rat Embolic Stroke Model

Originally published 2022;53:AWMP9

    Background: Our objective was to characterize the pharmacodynamic changes induced by NTS-104/105 within the brain and plasma in rats following embolic middle cerebral artery occlusion (eMCAO). Previous pharmacokinetic analysis indicated that NTS-104 is rapidly metabolized in the blood to form the active compound NTS-105, which is readily detected in the brain. In contrast, NTS-104 does not cross the blood-brain barrier.

    Methods: Adult, male Wistar rats were subjected to eMCAO. Stroke severity was defined by Neurological Severity Score (NSS) assessment. Only rats that scored >8 on a 13-point scale were included. Rats were dosed IM with vehicle, or NTS-104 (5mg/kg or 20mg/kg) at 6 hours after stroke. Brain and plasma samples rats were collected at 6, 12, or 24hrs after injection. Samples were screened for expression of AKT, pAKT and against a panel of 67 cytokines by quantitative ELISA.

    Results: We found that NTS-104 treatment induced a significant reduction in IL-6, GM-CSF, MCP-1, IL-1α, RAGE, VEGF, and ICAM-1 levels within the brains of rats following intramuscular injection of 20 mg/kg NTS-104 at 6-hours after eMCAO compared to vehicle treated control rats. In contrast, treatment with 5mg/kg NTS-104 did not induce similar time and dose dependent changes in these specific cytokines relative to vehicle treated controls. NTS-104 treatment also significantly reduced IL-6 and GM-CSF levels, while increasing galectin-1 levels, within the plasma of these same rats in a time and dose dependent manner similar to what was observed within the brain. We further detected a significant increase in the levels of phosphorylated AKT (pAKT) within the brains of stroked rats treated with 20 mg/kg NTS-104 but not with 5 mg/kg.

    Conclusion: These data demonstrate that treatment with NTS-104 results in the significant activation of the AKT cell survival signaling pathway and significantly reduces critical neuroinflammatory signaling after stroke in a time and dose dependent manner.


    Author Disclosures: For author disclosure information, please visit the ASA International Stroke Conference 2022 Online Program Planner and search for the abstract title.


    eLetters should relate to an article recently published in the journal and are not a forum for providing unpublished data. Comments are reviewed for appropriate use of tone and language. Comments are not peer-reviewed. Acceptable comments are posted to the journal website only. Comments are not published in an issue and are not indexed in PubMed. Comments should be no longer than 500 words and will only be posted online. References are limited to 10. Authors of the article cited in the comment will be invited to reply, as appropriate.

    Comments and feedback on AHA/ASA Scientific Statements and Guidelines should be directed to the AHA/ASA Manuscript Oversight Committee via its Correspondence page.